Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma

  • Technology appraisal guidance
  • TA321
  • Published: 
Download guidance (PDF)

Update information

Minor changes since publication

April 2017: The company changed from GlaxoSmithKline to Novartis. Contact details for the patient access scheme were updated.

ISBN: 978-1-4731-0805-9